Global Gemcitabine HCL Market - 2022-2029

Global Gemcitabine HCL Market - 2022-2029

Market Overview

Gemcitabine HCL Market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of X% during the forecast period (2022-2029).

Gemcitabine HCL is an FDA-approved drug with antineoplastic activity. It can be taken as a stand-alone or with other drugs. It is used for breast cancer, non-small cell cancer, ovarian cancer, pancreatic cancer, and others. This medication is given to the patient by injection into a vein by healthcare professionals. The dosage is based on the patient’s medical condition, body size, and response to treatment.

Market Dynamics

The gemcitabine HCL market growth is driven by several factors, such as an increase in the geriatric population, an increase in cancer diseases, technological advancements, and research activities for improvising the treatment.

The prevalence of cancer disease is expected to drive the market growth

The rise in breast cancer, pancreatic cancer, and many more is increasing the demand for gemcitabine HCL globally. According to the World Health Organization (WHO), cancer is the main cause of death globally. Approximately 10 million deaths in 2020 will be due to cancer, or nearly one in six deaths of patients. The most common cancers are breast, lung, colon, rectum, and prostate cancers. Around one-third of all cancer deaths are due to high body mass index, alcohol consumption, tobacco use, low vegetable, and fruit intake, and lack of physical activity. According to WHO data from February 2022, in 2020, there will be 2.26 million cases of breast cancer, 2.21 million cases of lung cancer, 1.20 million cases of skin cancer, and 1.93 million cases of colon and rectum cancer worldwide. In addition, every year, 400,000 children develop cancer. Cervical cancer is the most common cancer. The incidence of cancer disease increases with age, mostly due to risk factors building up for specific cancers that rise with age. To treat a cancer patient, it is necessary to diagnose cancer on time. Many cancers can be cured if detected early and treated effectively. In the proper selection of treatment, both cancer and the individual are considered for treatment. Gemcitabine HCL is given intravenously and belongs to a family of drugs called antimetabolites, which are very similar to normal substances within the cell. It is cell-cycle specific. When the cells incorporate these substances into the cellular metabolism, they are unable to divide. Mainly, it shows anitumor effects by promoting programmed cell death of cancer cells undergoing DNA synthesis. Specifically it blocks progression of cells through the G1/S-phase boundary. That's how it prevents the division of cells and prevents different cancers.

The side effects of gemcitabine HCL will hamper the growth of the market

However, studies have shown side effects of gemcitabine HCL, such as unusual weakness, loss of appetite, dark urine, pain spreading to the arm or shoulder, sudden severe headache fever, chills, body aches, flu symptoms, hearing problems, breathing problems, and chest pain and heavy feeling. These side effects create health risks among patients, which may adversely affect the market's growth.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global demand for these drugs due to their antiviral activity. In order to prevent the novel virus from rising into a pandemic human pathogen, it is essential that public health professionals can diagnose the infection, control its spread, and treat its causes. For instance, due to the antiviral activity of gemcitabine, HCL is compiled in the list of drugs with the potential to be used in the treatment of COVID-19 infection based on experience in treating a subsequence of viral diseases such as MERS-CoV and SARS-CoV infection. Gemcitabine hydrochloride is one of the nucleoside analog inhibitors for this purpose. It is valid for the treatment of SARS-CoV-2 treatment. Due to this, the demand is high in the market to treat the infection. As the cases of coronavirus rise worldwide, the demand has increased worldwide. For instance, as per the WHO data report of September 2022, the confirmed cases of coronaviruses are 609,848,852 globally.

On the other hand, many patients faced difficulty receiving their regular treatments during the pandemic due to transportation restrictions and lockdowns. However, because the situation is reversing in the middle of 2022 rather than 2021, the patient can now receive treatment in the hospital. The market will also show good growth in the forecast period.

Segment Analysis

The pancreas cancer segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The pancreatic cancer segment is expected to hold the dominant market share over the period forecast (2022–2029). Pancreatic cancer is one of the cancers with high mortality and has a common survival rate of 6–8%. In recent years, cancer has been proven to be one of the deadliest in the United States, with high morbidity, typically in elderly patients. Nowadays, there exists a large unmet need for drugs and drug delivery vehicles that can provide excellent therapeutic advantages. Substantial interest in Gemcitabine as a combination therapy is gathering among researchers. An increasing body of studies on its pharmacology has propelled the revenue potential of key players in this segment. Furthermore, pancreatic cancer accounts for 8% of male deaths and 8% of female deaths in the United States, according to the American Cancer Society. In the United States, new cancer cases occur in 3% of males and 3% of females. In addition, more than 90% of cases develop in the exocrine tissue of the pancreas, which helps enzymes digest food. The less common endocrine tumors, mainly referred to as pancreatic neuroendocrine tumours (NETs), develop in hormone-producing cells and have a younger median age at diagnosis and better prediction.

Geographical Analysis

North America region holds the largest market share of the global gemcitabine HCL market

North America dominates the market for gemcitabine HCL and is expected to show a similar trend over the forecast period owing to the increased geriatric population, advanced healthcare infrastructure, increased incidences of cancer diseases, and favorable government initiatives. As per the American Cancer Society, Inc., 2022 report, nearly 1.9 million new cases are anticipated to be diagnosed in the U.S. alone, and there are 609,360 cancer deaths in the United States due to cancer. As we increase in age, there is a risk of developing cancer. 80% of the population diagnosed with cancer in the US is 55 years of age or older, and 57% are 65 or older due to certain behaviors such as drinking alcohol, eating habits, smoking, and having excess body weight. In addition, in the United States, it is estimated that 40 out of 100 men and 39 out of 100 women will develop cancer during their life span. With the increased number of cancer cases, there is more demand for gemcitabine HCL in the market to treat different cancers in patients.

Competitive Landscape

The gemcitabine HCL market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Accord-UK Ltd., Pfizer, Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Fresenius Kabi AG, Dr. Reddy’s Laboratories Ltd., Ingenus Pharmaceuticals and NuCana Biomed’s among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the gemcitabine HCL market globally.

For instance,

• In September 2022, NuCana plc announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Acelarin (NUC-1031), derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. It is currently evaluated in a Phase III study for the first-line treatment of patients with advanced biliary tract cancer.

Stryker Corporation

Overview:

Eli Lilly and Company is an American pharmaceutical company headquartered in Indiana, founded in 1876, with a presence in 18 countries. The company receives profit from the marketing of its products for various cancer types for which gemcitabine HCL has been approved.

Product Portfolio:

Gemcitabine HCL:

Gemcitabine HCL is an oncology product for various cancer types. It is FDA approved for the treatment of breast cancer, non-small cell lung cancer, ovarian cancer, pancreatic cancer, and bladder cancer. In addition, it has been studied for its cytotoxic effect in various types of tumour treatment, including esophageal cancer.

The global Gemcitabine HCL market report would provide access to approximately 55+ market data tables, 50+ figures, and in the range of 250 (approximate) pages.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.